Characteristics | Total population (n = 997) | TIMI 0–2 flow (n = 489) | TIMI 3 flow (n = 508) | p Value |
Baseline characteristics | ||||
Age, years, median (IQR) | 59 (50–71) | 60 (51–72) | 58 (50–70) | 0.054 |
Women | 177 (18) | 90 (18) | 87 (17) | 0.587 |
Weight (kg), median (IQR) | 75 (69–85) | 77 (69–85) | 75 (69–85) | 0.275 |
BMI (kg/m2), median (IQR) | 26.1 (23.9–28.7) | 26.2 (24.2–29.1) | 25.8 (23.9–28.7) | 0.133 |
SBP (mm Hg), median (IQR) | 132 (120–150) | 131 (120–151) | 132 (120–150) | 0.868 |
DBP (mm Hg), median (IQR) | 80 (70–90) | 80 (70–91) | 80 (70–90) | 0.535 |
Heart rate (bpm), median (IQR) | 72 (60–84) | 72 (60–85) | 70 (60–82) | 0.366 |
Killip class I | 882 (91) | 423 (89) | 459 (93) | 0.019 |
Medical history | ||||
Coronary artery disease | 157 (16) | 80 (17) | 77 (16) | 0.666 |
Myocardial infarction | 83 (9) | 44 (9) | 39 (8) | 0.476 |
PCI | 73 (8) | 31 (7) | 42 (9) | 0.226 |
CABG | 9 (1) | 4 (1) | 5 (1) | 0.999 |
Peripheral arterial disease | 23 (2) | 6 (1) | 17 (4) | 0.026 |
Stroke/TIA | 19 (2) | 10 (2) | 9 (2) | 0.763 |
Hypertension | 365 (40) | 196 (43) | 169 (36) | 0.027 |
Hyperlipidaemia | 399 (46) | 204 (48) | 195 (44) | 0.237 |
Diabetes | 139 (15) | 69 (16) | 70 (15) | 0.837 |
Smoking | 0.013 | |||
Never smoked | 281 (30) | 160 (35) | 121 (26) | |
Current smoker | 406 (44) | 187 (41) | 219 (47) | |
Past smoker | 235 (26) | 111 (24) | 124 (27) | |
Previous medical prescriptions | ||||
Aspirin | 132 (13) | 63 (13) | 69 (14) | 0.699 |
Thienopyridine | 22 (2) | 11 (2) | 11 (2) | 0.946 |
β Blocker | 133 (13) | 71 (15) | 62 (12) | 0.310 |
ACE inhibitor | 139 (14) | 69 (14) | 70 (14) | 0.929 |
Calcium channel blocker | 103 (10) | 56 (11) | 47 (9) | 0.276 |
Statin | 149 (15) | 71 (15) | 78 (16) | 0.664 |
Vitamin K antagonist | 11 (1) | 3 (1) | 8 (2) | 0.142 |
IV nitrate or vasodilator | 65 (7) | 28 (6) | 37 (7) | 0.300 |
Baseline ECG characteristics | ||||
Anterior myocardial infarction | 417 (42) | 219 (45) | 198 (39) | 0.070 |
Maximum ST elevation (mm), median (IQR) | 3 (2–5) | 3 (2–5) | 3 (2–5) | 0.067 |
Number of leads with ST elevation, median (IQR) | 4 (3–5) | 4 (3–6) | 4 (3–5) | 0.008 |
Thrombolysis | ||||
Tenecteplase | 957 (96) | 472 (97) | 485 (96) | 0.432 |
Alteplase | 17 (2) | 6 (1) | 11 (2) | |
Reteplase | 19 (2) | 8 (2) | 11 (2) | |
Acute phase treatments in MICU | ||||
Aspirin | 931 (94) | 459 (94) | 472 (94) | 0.982 |
Heparin | 966 (97) | 477 (98) | 489 (97) | 0.272 |
Thienopyridine | 72 (9) | 42 (10) | 30 (7) | 0.077 |
Glycoprotein IIb/IIIa inhibitor | 22 (3) | 13 (3) | 9 (2) | 0.291 |
β Blocker | 107 (13) | 49 (12) | 58 (13) | 0.643 |
IV nitrate | 360 (40) | 179 (42) | 181 (39) | 0.397 |
Changes after acute phase treatments | ||||
AIVR | 149 (16) | 63 (14) | 86 (18) | 0.082 |
ST resolution ⩾70% * | 332 (41) | 125 (32) | 207 (51) | <0.001 |
Chest pain relief* | 350 (43) | 136 (35) | 214 (51) | <0.001 |
Killip class I* | 912 (92) | 436 (89) | 476 (94) | 0.010 |
Coronary angiography data | ||||
Infarct artery | ||||
Left main coronary | 7 (1) | 3 (1) | 4 (1) | |
Left anterior descending | 413 (41) | 223 (45) | 190 (37) | |
Left circumflex | 120 (12) | 47 (10) | 73 (14) | |
Right coronary | 439 (44) | 211 (43) | 228 (45) | |
Bypass graft | 2 (<1) | 1 (<1) | 1 (<1) | |
Undetermined | 16 (2) | 4 (1) | 12 (2) | |
Stenosis of the infarct artery ⩾50% | 936 (94) | 469 (96) | 467 (92) | |
Vessels with stenosis ⩾50% | ||||
0 | 44 (5) | 9 (2) | 35 (7) | |
1 | 546 (55) | 285 (58) | 261 (52) | |
2 | 262 (26) | 128 (26) | 134 (27) | |
3 | 140 (14) | 67 (14) | 73 (14) | |
TIMI flow grade before any PCI | ||||
0 | 189 (19) | – | – | |
1 | 40 (4) | – | – | |
2 | 260 (26) | – | – | |
3 | 508 (51) | – | – |
Values given as n (%) unless stated otherwise. For each index item, the percentage was calculated on the number of patients without missing data for the variable (missing data were <10% except for BMI, hypercholesterolaemia (⩽13%), β blocker, thienopyridine or glycoprotein IIb/IIIa inhibitor (⩽16%) and chest pain relief (19%)). Percentages on ST resolution were calculated on 800 patients.
*Assessment before coronary angiography.
ACE, angiotensin-converting enzyme; AIVR, accelerated idioventricular rhythm; BMI, body mass index; CABG, coronary artery bypass graft; DBP, diastolic blood pressure; IV, intravenous; MICU, mobile intensive care unit; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; TIA, transient ischaemic attack.